FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W101377834> ?p ?o ?g. }

• W101377834 endingPage "2482" @default.
• W101377834 startingPage "2471" @default.
• W101377834 abstract "The balance between stroke reduction and increased bleeding associated with antithrombotic therapy among patients with atrial fibrillation (AF) and chronic kidney disease (CKD) is controversial. This study assessed the risk associated with CKD in individual CHA2DS2-VASc (Congestive heart failure; Hypertension; Age ≥75 years; Diabetes mellitus; previous Stroke, transient ischemic attack, or thromboembolism; Vascular disease; Age 65 to 74 years; Sex category) strata and the net clinical benefit of warfarin in patients with AF and CKD in a nationwide cohort. By individual-level linkage of nationwide Danish registries, we identified all patients discharged with nonvalvular AF from 1997 to 2011. The stroke risk associated with non-end-stage CKD and end-stage CKD (e.g., patients on renal replacement therapy [RRT]) was estimated using Cox regression analyses. The net clinical benefit of warfarin was assessed using 4 endpoints: a composite endpoint of death/hospitalization from stroke/bleeding; a composite endpoint of fatal stroke/fatal bleeding; cardiovascular death; and all-cause death. From nonvalvular AF patients (n = 154,259), we identified 11,128 patients (7.2%) with non-end-stage CKD and 1,728 (1.1%) receiving RRT. In all CHA2DS2-VASc risk groups, RRT was independently associated with a higher risk of stroke/thromboembolism, from a 5.5-fold higher risk in patients with CHA2DS2-VASc score = 0 to a 1.6-fold higher risk in patients with CHA2DS2-VASc score ≥2. In patients receiving RRT with CHA2DS2-VASc score ≥2, warfarin was associated with lower risk of all-cause death (hazard ratio [HR]: 0.85, 95% confidence interval [CI]: 0.72 to 0.99). In non-end-stage CKD patients with CHA2DS2-VASc score ≥2, warfarin was associated with a lower risk of a composite outcome of fatal stroke/fatal bleeding (HR: 0.71, 95% CI: 0.57 to 0.88), a lower risk of cardiovascular death (HR: 0.80, 95% CI: 0.74 to 0.88), and a lower risk of all-cause death (HR: 0.64, 95% CI: 0.60 to 0.69). CKD is associated with a higher risk of stroke/thromboembolism across stroke risk strata in AF patients. High-risk CKD patients (CHA2DS2-VASc ≥2) with AF benefit from warfarin treatment for stroke prevention." @default.
• W101377834 created "2016-06-24" @default.
• W101377834 creator A5004642904 @default.
• W101377834 creator A5018763521 @default.
• W101377834 creator A5028361516 @default.
• W101377834 creator A5039739369 @default.
• W101377834 creator A5041526130 @default.
• W101377834 creator A5048371995 @default.
• W101377834 creator A5050037180 @default.
• W101377834 creator A5077151959 @default.
• W101377834 creator A5087431344 @default.
• W101377834 creator A5088579117 @default.
• W101377834 date "2014-12-01" @default.
• W101377834 modified "2023-10-14" @default.
• W101377834 title "Net Clinical Benefit of Antithrombotic Therapy in Patients With Atrial Fibrillation and Chronic Kidney Disease" @default.
• W101377834 cites W1490007665 @default.
• W101377834 cites W173028345 @default.
• W101377834 cites W1970090549 @default.
• W101377834 cites W1981440884 @default.
• W101377834 cites W1999468381 @default.
• W101377834 cites W1999877119 @default.
• W101377834 cites W2025282593 @default.
• W101377834 cites W2028298306 @default.
• W101377834 cites W2054077136 @default.
• W101377834 cites W2067443499 @default.
• W101377834 cites W2069108810 @default.
• W101377834 cites W2073789348 @default.
• W101377834 cites W2078568576 @default.
• W101377834 cites W2093469848 @default.
• W101377834 cites W2100505398 @default.
• W101377834 cites W2102420102 @default.
• W101377834 cites W2102924526 @default.
• W101377834 cites W2117807413 @default.
• W101377834 cites W2123869153 @default.
• W101377834 cites W2130977972 @default.
• W101377834 cites W2132169906 @default.
• W101377834 cites W2137138584 @default.
• W101377834 cites W2138320008 @default.
• W101377834 cites W2140015099 @default.
• W101377834 cites W2142749836 @default.
• W101377834 cites W2147108549 @default.
• W101377834 cites W2150445125 @default.
• W101377834 cites W2160860313 @default.
• W101377834 cites W2162586165 @default.
• W101377834 cites W2163399076 @default.
• W101377834 cites W2165582367 @default.
• W101377834 cites W2171838412 @default.
• W101377834 cites W3030533492 @default.
• W101377834 doi "https://doi.org/10.1016/j.jacc.2014.09.051" @default.
• W101377834 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25500231" @default.
• W101377834 hasPublicationYear "2014" @default.
• W101377834 type Work @default.
• W101377834 sameAs 101377834 @default.
• W101377834 citedByCount "246" @default.
• W101377834 countsByYear W1013778342013 @default.
• W101377834 countsByYear W1013778342014 @default.
• W101377834 countsByYear W1013778342015 @default.
• W101377834 countsByYear W1013778342016 @default.
• W101377834 countsByYear W1013778342017 @default.
• W101377834 countsByYear W1013778342018 @default.
• W101377834 countsByYear W1013778342019 @default.
• W101377834 countsByYear W1013778342020 @default.
• W101377834 countsByYear W1013778342021 @default.
• W101377834 countsByYear W1013778342022 @default.
• W101377834 countsByYear W1013778342023 @default.
• W101377834 crossrefType "journal-article" @default.
• W101377834 hasAuthorship W101377834A5004642904 @default.
• W101377834 hasAuthorship W101377834A5018763521 @default.
• W101377834 hasAuthorship W101377834A5028361516 @default.
• W101377834 hasAuthorship W101377834A5039739369 @default.
• W101377834 hasAuthorship W101377834A5041526130 @default.
• W101377834 hasAuthorship W101377834A5048371995 @default.
• W101377834 hasAuthorship W101377834A5050037180 @default.
• W101377834 hasAuthorship W101377834A5077151959 @default.
• W101377834 hasAuthorship W101377834A5087431344 @default.
• W101377834 hasAuthorship W101377834A5088579117 @default.
• W101377834 hasConcept C126322002 @default.
• W101377834 hasConcept C127413603 @default.
• W101377834 hasConcept C134018914 @default.
• W101377834 hasConcept C164705383 @default.
• W101377834 hasConcept C207103383 @default.
• W101377834 hasConcept C2776301958 @default.
• W101377834 hasConcept C2777015399 @default.
• W101377834 hasConcept C2778198053 @default.
• W101377834 hasConcept C2778653478 @default.
• W101377834 hasConcept C2779161974 @default.
• W101377834 hasConcept C2780645631 @default.
• W101377834 hasConcept C44249647 @default.
• W101377834 hasConcept C50382708 @default.
• W101377834 hasConcept C555293320 @default.
• W101377834 hasConcept C71924100 @default.
• W101377834 hasConcept C78519656 @default.
• W101377834 hasConceptScore W101377834C126322002 @default.
• W101377834 hasConceptScore W101377834C127413603 @default.
• W101377834 hasConceptScore W101377834C134018914 @default.
• W101377834 hasConceptScore W101377834C164705383 @default.
• W101377834 hasConceptScore W101377834C207103383 @default.
• W101377834 hasConceptScore W101377834C2776301958 @default.

• next